S. Tekin, Ş. Sümer, N. Demirtürk, B. Aygen
{"title":"Chronic Hepatitis C in the Pandemic","authors":"S. Tekin, Ş. Sümer, N. Demirtürk, B. Aygen","doi":"10.36519/KD.2021.03","DOIUrl":null,"url":null,"abstract":"Corona virus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, affected all the world and has been a major cause for significant morbidity and mortality. COVID-19 represents with pulmonary manifestations, but in more than half of the cases, other organs, especially hepatic involvement, are observed. Chronic hepatitis C (CHC) is an important public health problem worldwide. Sustained virological response (SVR) can be achieved and HCV-related mortality and morbidity can be prevented with direct-acting antiviral agents (DAAs), which have been used in recent years. However, if CHC is not diagnosed, it can cause cirrhosis and liver cancer. Since the diagnosis and treatment of these patients require follow-up, they are among the most affected chronic diseases during the pandemic. It does not seem possible to predict when the COVID-19 outbreak will end. Diagnosis and treatment need of CHC patients should be met in special areas where protection measures are taken in health institutions. In patients who undergo DAA treatment, the follow-up should be carried out by health institutions that do not provide pandemic services, and if necessary, telemedicine should be used. © 2021, DOC Design and Informatics Co. Ltd.. All rights reserved.","PeriodicalId":17826,"journal":{"name":"Klimik Dergisi/Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klimik Dergisi/Klimik Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36519/KD.2021.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
慢性丙型肝炎大流行
由严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2)病毒引起的2019年冠状病毒病(COVID-19)影响了全世界,并已成为导致大量发病率和死亡率的主要原因。COVID-19以肺部表现为特征,但在一半以上的病例中,可观察到其他器官,特别是肝脏受累。慢性丙型肝炎(CHC)是世界范围内一个重要的公共卫生问题。使用近年来使用的直接作用抗病毒药物(DAAs)可以实现持续的病毒学应答(SVR),并预防hcv相关的死亡率和发病率。然而,如果CHC没有被诊断出来,它可能会导致肝硬化和肝癌。由于这些患者的诊断和治疗需要随访,因此它们属于大流行期间受影响最大的慢性病。预计新冠疫情何时结束似乎是不可能的。在卫生机构采取保护措施的特殊区域,应满足CHC患者的诊断和治疗需求。在接受DAA治疗的患者中,随访应由不提供大流行服务的卫生机构进行,必要时应使用远程医疗。©2021,DOC Design and Informatics Co. Ltd。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。